Cargando…
Multistage pH-responsive codelivery liposomal platform for synergistic cancer therapy
BACKGROUND: Small interfering RNA (siRNA) is utilized as a potent agent for cancer therapy through regulating the expression of genes associated with tumors. While the widely application of siRNAs in cancer treatment is severely limited by their insufficient biological stability and its poor ability...
Autores principales: | Zhao, Ting, Liang, Ce, Zhao, Yanrong, Xue, Xiangdong, Ma, Zhao, Qi, Jinlong, Shen, Haitao, Yang, Shaokun, Zhang, Jia, Jia, Qingzhong, Du, Qing, Cao, Deying, Xiang, Bai, Zhang, Hailin, Qi, Xianrong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8976966/ https://www.ncbi.nlm.nih.gov/pubmed/35366888 http://dx.doi.org/10.1186/s12951-022-01383-z |
Ejemplares similares
-
Codelivery of Doxorubicin and Paclitaxel by Cross-Linked
Multilamellar Liposome Enables Synergistic Antitumor Activity
por: Liu, Yarong, et al.
Publicado: (2014) -
pH-Responsive, Adorned Nanoniosomes for Codelivery
of Cisplatin and Epirubicin: Synergistic Treatment of Breast Cancer
por: Moammeri, Ali, et al.
Publicado: (2022) -
Nucleus-selective codelivery of proteins and drugs for synergistic antitumor therapy
por: Yang, Lan, et al.
Publicado: (2022) -
Self-Assembling pH-Responsive Nanoparticle Platform
Based on Pectin–Doxorubicin Conjugates for Codelivery of Anticancer
Drugs
por: Tao, Yinghua, et al.
Publicado: (2021) -
Docetaxel and Doxorubicin Codelivery by Nanocarriers for Synergistic Treatment of Prostate Cancer
por: Li, Ke, et al.
Publicado: (2019)